These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18383522)

  • 1. Visilizumab in severe ulcerative colitis: good vision but blurry results.
    Sparrow M
    Inflamm Bowel Dis; 2008 Jul; 14(7):1022-3. PubMed ID: 18383522
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the risk of epstein-barr virus-related lymphoproliferative disorders before administration of visilizumab.
    Guthery SL; Gross TG
    Gastroenterology; 2008 Mar; 134(3):895-6. PubMed ID: 18325408
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
    Plevy S; Salzberg B; Van Assche G; Regueiro M; Hommes D; Sandborn W; Hanauer S; Targan S; Mayer L; Mahadevan U; Frankel M; Lowder J
    Gastroenterology; 2007 Nov; 133(5):1414-22. PubMed ID: 17920064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
    Sandborn WJ; Colombel JF; Frankel M; Hommes D; Lowder JN; Mayer L; Plevy S; Stokkers P; Travis S; Van Assche G; Baumgart DC; Targan SR
    Gut; 2010 Nov; 59(11):1485-92. PubMed ID: 20947884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways.
    Yu QT; Saruta M; Papadakis KA
    Clin Immunol; 2008 Jun; 127(3):322-9. PubMed ID: 18424236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
    Baumgart DC; Targan SR; Dignass AU; Mayer L; van Assche G; Hommes DW; Hanauer SB; Mahadevan U; Reinisch W; Plevy SE; Salzberg BA; Buchman AL; Mechkov GM; Krastev ZA; Lowder JN; Frankel MB; Sandborn WJ
    Inflamm Bowel Dis; 2010 Apr; 16(4):620-9. PubMed ID: 19714757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etrolizumab in moderate-to-severe ulcerative colitis.
    Armuzzi A; Felice C
    Lancet; 2014 Jul; 384(9940):285-6. PubMed ID: 24814088
    [No Abstract]   [Full Text] [Related]  

  • 8. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa.
    Fiorino G; Danese S
    Gastroenterology; 2014 Dec; 147(6):1433-5. PubMed ID: 25457851
    [No Abstract]   [Full Text] [Related]  

  • 10. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab in ulcerative colitis: hypes and hopes.
    Fiorino G; Peyrin-Biroulet L; Repici A; Malesci A; Danese S
    Expert Opin Biol Ther; 2011 Jan; 11(1):109-16. PubMed ID: 21133817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus colitis complicating ulcerative colitis treated with adalimumab.
    Charles P; Ackermann F; Burdy G; Blétry O; Leport J; Kahn JE
    Scand J Gastroenterol; 2010 Apr; 45(4):509-10. PubMed ID: 20095878
    [No Abstract]   [Full Text] [Related]  

  • 13. Does it all ADA up? Adalimumab for ulcerative colitis.
    Travis S
    Gut; 2011 Jun; 60(6):741-2. PubMed ID: 21257988
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Moss AC; Farrell RJ
    Gastroenterology; 2006 Nov; 131(5):1649-51; discussion 1651. PubMed ID: 17067595
    [No Abstract]   [Full Text] [Related]  

  • 19. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC; Prather CM
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract]   [Full Text] [Related]  

  • 20. Onset of ulcerative colitis under treatment with adalimumab.
    Tursi A; Penna A
    Am J Gastroenterol; 2008 Sep; 103(9):2410-2. PubMed ID: 18844636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.